Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q2 2026

Celularity Q2 2026 Results: Turns Profitable, Net Income $706K

Celularity Inc. reported a significant decrease in cash and cash equivalents from $6.18 million at the end of 2025 to $586,000 as of June 30, 2026. The company's total assets declined to $96.2 million, while it continues to focus on cellular therapy development and commercializing its biomaterials products.

Q2 2026 at a glance · $ million
MetricQ2 2026Q2 2025
Revenue5.45.7
Profit before tax0.7-24.5
Net income0.7-24.5
EPS (diluted, $ a share)$0.02$-1.02

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year-5.3%
Operating margin-78.0%
Source

10-Q filed with the SEC, NASDAQ: CELU. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Celularity Inc: key numbers

Share price
$0.6191Close, Nov 16
Market cap
$20.1M
Shares outstanding
32.45MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Celularity Inc

All →
9:25 AM ET 8-K
Partnership

Celularity Partnership with Vesalius Longevity Labs Inc.

Celularity entered into an exclusive manufacturing and commercial collaboration with Vesalius Longevity Labs to establish a U.S.-based manufacturing and supply platform for Peptual-branded peptide active pharmaceutical ingredients (APIs). Celularity will utilize its Florham Park, New Jersey facility to perform downstream purification, processing, and analytical testing of bulk peptide material under cGMP standards.

Counterparty
Vesalius Longevity Labs Inc.
5:26 PM ET 8-K
Leadership Change

Celularity Leadership Change

Celularity Inc. appointed Naveen Jain, founder and CEO of Viome Life Sciences, to its Board of Directors. Mr. Jain was designated for the role by investors from a recent September 2026 financing, and his appointment coincides with the resignation of director Diane Parks.

Counterparty
Naveen Jain
6:15 AM ET 8-K
Loan & Debt

Celularity $25M Debt Financing

Celularity Inc. entered into a Securities Purchase Agreement to issue up to $25.0 million in senior secured convertible promissory notes and warrants across two tranches. The company completed an initial closing of approximately $11.01 million in principal amount, with the notes bearing 10% interest and maturing in 24 months.

Value
$25M
Term
24 months
9:01 AM ET 8-K
Nasdaq/NYSE Compliance Notice

Celularity Nasdaq/NYSE Compliance Notice

Celularity Inc. has regained compliance with Nasdaq's minimum bid price and minimum market value of listed securities requirements. However, the company remains deficient regarding the timely filing of its periodic reports and is working to complete those filings to fully regain compliance.

Counterparty
The Nasdaq Stock Market LLC

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.